evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,703 questions · 15,007 findings · 1,416 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 2,881 · 19.2%GRADE not reported 1,551 · 10.3%Very low 3,111 · 20.7%Low 3,881 · 25.9%Moderate 2,669 · 17.8%High 914 · 6.1%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

NB‐UVB vs placebo

Patient‐reported changes in symptoms · atopic eczema

Summary of findings table ‐ NB‐UVB may leads to higher patient‐reported changes in symptoms compared with placebo (low certainty).

1 finding from 1 review

NB‐UVB vs placebo

Investigator Global Assessment · atopic eczema

Summary of findings table ‐ NB‐UVB may leads to higher investigator Global Assessment (short‐term) compared with placebo (low certainty).

1 finding from 1 review

NB‐UVB vs placebo

Health‐related quality of life ‐ not measured · atopic eczema

The review found no eligible studies for this question.

1 finding from 1 review

Rituximab vs placebo

Common infections measured by clinical assessment over 28 months · primary progressive multiple sclerosis

Rituximab as 'first choice' showed no clear difference in common infections measured by clinical assessment over 28 months compared with placebo (low certainty).

1 finding from 1 review

Rituximab vs placebo

Cancer · primary progressive multiple sclerosis

Rituximab as 'first choice' showed no clear difference in cancer measured by clinical assessment over 28 months compared with placebo (low certainty).

1 finding from 1 review

Rituximab vs placebo

Mortality measured by clinical assessment over 12 months · primary progressive multiple sclerosis

Rituximab as 'first choice' showed no clear difference in mortality measured by clinical assessment over 28 months compared with placebo (low certainty).

1 finding from 1 review

Rituximab vs placebo

Clinical relapse · relapsing multiple sclerosis

Rituximab as 'switching' may leads to lower relapse measured by clinical assessment over 12 months compared with placebo (low certainty).

1 finding from 1 review

Rituximab vs placebo

Serious adverse events measured by clinical assessment over 12 months · relapsing multiple sclerosis

It is very uncertain whether rituximab as 'switching' changes serious adverse events measured by clinical assessment over 12 months compared with placebo (very low certainty).

1 finding from 1 review

Rituximab vs placebo

Common infections measured by clinical assessment over 12 months · relapsing multiple sclerosis

It is very uncertain whether rituximab as 'switching' changes common infections measured by clinical assessment over 12 months compared with placebo (very low certainty).

1 finding from 1 review

Rituximab vs placebo

Cancer · relapsing multiple sclerosis

It is very uncertain whether rituximab as 'switching' changes cancer measured by clinical assessment over 12 months compared with placebo (very low certainty).

1 finding from 1 review

Rituximab vs placebo

Mortality measured by clinical assessment over 12 months · relapsing multiple sclerosis

It is very uncertain whether rituximab as 'switching' changes mortality measured by clinical assessment over 12 months compared with placebo (very low certainty).

1 finding from 1 review

Rituximab vs placebo

Disability worsening · primary progressive multiple sclerosis

Rituximab as 'first choice' showed no clear difference in disability worsening measured by EDSS over 24 months compared with placebo (moderate certainty).

1 finding from 1 review

Rituximab vs placebo

Clinical relapse · primary progressive multiple sclerosis

Rituximab as 'first choice' showed no clear difference in relapse measured by clinical assessment over 24 months compared with placebo (low certainty).

1 finding from 1 review

Rituximab vs placebo

Serious adverse events measured by clinical assessment over 12 months · primary progressive multiple sclerosis

Rituximab as 'first choice' showed no clear difference in serious adverse events measured by clinical assessment over 28 months compared with placebo (low certainty).

1 finding from 1 review